Iclusig (Ponatinib)

Related Products

• Product Details

  Description

  Inclusig (ponatinib) is prescribed for the treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia and Chronic Myeloid Leukemia in adults.

  Inclusig is available in 10 mg, 15 mg, 30 mg, and 45 mg oral tablets.

  Fact Table
  Formula	C29H27F3N6O
  License	US FDA, EMA
  Bioavailability	52%
  Legal status	Prescription only (Rx)
  Chemical Name	3-(2-Imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-{(4-methylpiperazin-1-yl)methyl}-3-(trifluoromethyl)phenyl]benzamide
  Elimination half-life	24 hours
  Dosage (Strength)	15 mg, 30 mg, 45 mg tablets
  Pregnancy	Contraindicated
  Brands	Iclusig
  Protein binding	>99%
  PubChem CID	24826799
  MedlinePlus	a613020
  ChEBI	CHEBI:78543
  ATC code	L01XE24
  DrugBank	DB08943
  KEGG	D09925
  Routes of administration	Oral

  Directions

  Take Inclusig as prescribed by your doctor, who will determine an appropriate Inclusig dosage for you based on the condition being treated.

  Keep Inclusig tablets stored between 20°C to 25°C (68°F to 77°F) and out of reach of children.

  For additional information regarding the use of Inclusig, refer to the medication guide that comes with your prescription.

  If you have any questions or concerns, speak with your doctor or pharmacist.

  Ingredients

  The active ingredient in Inclusig is ponatinib.

  Inactive ingredients include lactose monohydrate, microcrystalline cellulose, sodium starch glycolate (type B), colloidal silicon dioxide, magnesium stearate and a tablet coating that consists of talc, polyethylene glycol, polyvinyl alcohol, and titanium dioxide.

  Contraindications

  According to the most recent Prescribing Information, there are no contraindications to taking Inclusig.

  Cautions

  • Inclusig contains the following FDA Boxed Warning:
  • Patients treated with Inclusig, including those with and without cardiovascular risk factors and younger than 50 years old, have had arterial occlusive events (AOEs), including mortality, heart attack, stroke, stenosis of large arterial brain vessels, severe peripheral vascular disease, and the need for urgent revascularization procedures. Evidence of AOEs should be monitored. Inclusig should be interrupted or stopped based on severity. Before restarting Inclusig, consider the benefits and risks.
  • Patients treated with Inclusig have experienced venous blood clotting. Monitoring should occur. Inclusig should be interrupted or stopped based on severity.
  • Patients treated with Inclusig had heart failure, including mortality. Heart failure should be monitored and managed when clinically indicated. Inclusig should be interrupted or stopped if new or worsening heart failure develops.
  • Patients treated with Inclusig have had liver toxicity, liver failure, and death. Liver function tests should be monitored. Inclusig should be interrupted or stopped based on severity.
  • Before you start treatment with Inclusig, talk to your doctor about:
  • All the prescription and over-the-counter medications you take
  • Your allergies
  • Your current health problems and past medical history
  • Your pregnancy or breastfeeding status
  • Inclusig contains the following warnings and precautions:
  • High blood pressure
  • Pancreatitis
  • Neuropathy
  • Eye problems
  • Major bleeding
  • Fluid retention
  • Heart arrhythmias
  • Decreased bone marrow activity
  • Tumor lysis syndrome
  • Reversible posterior leukoencephalopathy syndrome
  • Delayed wound healing and perforation of the stomach and intestines
  • Harm to an unborn baby; females who are capable of reproducing should use effective contraceptive methods during Inclusig treatment and for 3 weeks after taking the final dose.

  Side Effects

  Rash and related conditions, joint pain, abdominal pain, headache, constipation, dry skin, high blood pressure, fatigue, fluid retention and swelling, fever, nausea, pancreatitis/lipase elevation, major bleeding, anemia, liver problems, AOEs, and abnormal labs (decreased platelets, neutrophils, and white blood cells) are the most common side effects when using Inclusig by itself.

  Liver problems, joint pain, rash and related conditions, headache, fever, abdominal pain, constipation, fatigue, nausea, oral mucositis, high blood pressure, pancreatitis/lipase elevation, neuropathy peripheral, major bleeding, febrile neutropenia, fluid retention and swelling, vomiting, tingling/numbness, heart arrhythmias, and abnormal labs (decreased white blood cells, neutrophils, platelets, lymphocytes, and hemoglobin and increased lipase and alanine aminotransferase) are the most common side effects when using Inclusig with chemotherapy.

  Other side effects may occur. Immediately inform your doctor of any side effects that bother you or won’t go away.

  Searching for a competitive Inclusig price? You can buy Inclusig right here!

  Reference

  Inclusig. Lexington, MA: Takeda Pharmaceuticals America, Inc.; 2024.

  
  
  

  

  About Dr. Savannah Muncy (Page Author)

  
  Dr. Muncy (PharmD) studied science and education as an undergraduate before attending the Appalachian College of Pharmacy where she completed her PharmD in three years. She is currently using her pharmacy and healthcare expertise to write medical content for clients all around the world. She is focused on delivering the most current, accurate, and engaging information to healthcare professionals and patients. Read More....

  
  

  IMPORTANT NOTE: The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.

  Product Code : 14938

• Product Reviews